University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 10 of 16
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT02046421
The Effects of Buprenorphine on Responses to Verbal Tasks
NCT01860287
The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
NCT01928082
DBS Frequency on Swallowing Function in Parkinson's Disease
NCT01935011
Sleep for Inpatients: Empowering Staff to Act
NCT02025959
Comparing the Outcomes Between Rotator Cuff Repair With and Without Suprascapular Nerve Decompression
NCT02107573
Parkinsonism in Spinocerebellar Ataxia Type 6
NCT01934998
Use of Motivational Interviewing to Increase Contraception Use Among Young Women
NCT01881321
Impact of Video Intervention on Postabortal Uptake of Long Acting Reversible Contraception (LARC)
NCT01945385
Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer
NCT01949740
A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis
NCT02058524
Outcomes of Biceps Tenodesis or Labral Repair for Treatment of Type 2 Superior Labrum Anterior and Posterior Lesions
NCT02107547
Comparison of Outcomes Between Biceps Tenotomy and Tenodesis in the Treatment of the Long Head of the Biceps Pathology
NCT02107586
Patient Support During Surgical Abortion
NCT01937988
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT01816984
Inositol in Trichotillomania
NCT01875445
Double-Blind Treatment of Major Depressive Disorder With Vilazodone
NCT01742832
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01839916
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
NCT01847326
Active vs Passive Distraction on Procedural Pain in the Pediatric Emergency Department
NCT01960166
Communication Bridge Speech Therapy Research Study
NCT02439853
Impact of the CommunityRx Program on Health, Service Utilization and Costs
NCT02411409
Cannabidiol and Emotional Stimuli
NCT02902081
Dexamethasone and Lower Extremity Block Duration
NCT01756586
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
NCT01792024
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
NCT01803269
Allergic Rhinitis Changes the Sinus Microbiome
NCT01852513
Effect of Azilsartan on Aldosterone in Postmenopausal Females
NCT01774591
Comparison of Ultrasound Guided Low Epidural Catheter Placement With Standard Epidural Catheter Placement
NCT01182220
Dexamethasone and Block Duration in Upper Extremity
NCT01756573
Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair
NCT01756560
Network Supported Engagement In HIV Care
NCT01726712
Effect of Nasaleze on Nasal Challenge With Allergen
NCT01723397
Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement
NCT01988766
N-Acetyl Cysteine in Pathologic Skin Picking
NCT01063348
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
NCT01680783
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
NCT01705106
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01665794
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT01791088
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
NCT01839240
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
NCT01592383
Project ASPIRE Efficacy Pilot: Achieving Superior Parental Involvement for Rehabilitative Excellence
NCT01753661
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
NCT01599832
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
NCT01599793
Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients
NCT01592006
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
NCT01643499
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
NCT04726527
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
NCT00943319
Pain Assessment in the Intensive Care Unit
NCT01628185
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
NCT01543776
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.